恒瑞医药(600276.SH)：瑞拉芙普α注射液获得药品注册批准

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the launch of its independently developed innovative drug, Relafufup α injection [1] Group 1: Product Development - Relafufup α injection is a dual-function fusion protein targeting PD-L1/TGF-βRII, designed to specifically block the interaction between PD-1 and PD-L1 while neutralizing TGF-β in the tumor microenvironment, thereby exerting anti-tumor effects [1] - There are currently no similar products approved for market release domestically or internationally [1] Group 2: Investment and R&D - The cumulative research and development investment for the Relafufup α injection project has reached approximately 71.13 million yuan [1]